HomeIONS • NASDAQ
add
Ionis Pharmaceuticals Inc
Previous close
$40.69
Day range
$40.03 - $41.11
Year range
$23.95 - $50.37
Market cap
6.46B USD
Avg Volume
2.06M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 452.05M | 100.69% |
Operating expense | 90.62M | 39.18% |
Net income | 123.55M | 286.45% |
Net profit margin | 27.33 | 192.90% |
Earnings per share | 0.85 | 452.98% |
EBITDA | 142.68M | 326.46% |
Effective tax rate | -0.02% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.29B | 9.95% |
Total assets | 2.99B | 10.92% |
Total liabilities | 2.35B | -3.05% |
Total equity | 631.72M | — |
Shares outstanding | 159.39M | — |
Price to book | 10.25 | — |
Return on assets | 12.06% | — |
Return on capital | 13.82% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 123.55M | 286.45% |
Cash from operations | 151.34M | 226.24% |
Cash from investing | -120.07M | -292.26% |
Cash from financing | 1.25M | -51.23% |
Net change in cash | 33.11M | 160.32% |
Free cash flow | 98.52M | 197.53% |
About
Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza, Tegsedi, and Waylivra, and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.
The company was named Isis Pharmaceuticals until December 2015. Wikipedia
Founded
1989
Headquarters
Website
Employees
1,069
